CRYOPORT, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
CRYOPORT, INC. (CYRX) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $13.42 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $13.42M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $12.89M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $12.54M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $12.86M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $13.42M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $12.89M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $12.54M 10-K · filed 2026-03-05 |
| 2025-09-30 | $12.86M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $12.72M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $12.59M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $15.31M 10-K · filed 2025-03-07 |
| 2024-09-30 | $15.12M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $15.04M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $14.79M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $16.90M 10-K · filed 2024-03-13 |
| 2023-09-30 | $15.07M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $7.86M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $11.48M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $15.27M 10-K · filed 2023-02-28 |
| 2022-09-30 | $14.94M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $14.92M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $14.94M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $14.97M 10-K · filed 2022-02-28 |
| 2021-09-30 | $14.82M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $14.85M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $14.30M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $14.44M 10-K · filed 2021-03-01 |
| 2020-09-30 | $537.00K 10-Q · filed 2020-11-06 |
| 2019-12-31 | $537.00K 10-K · filed 2020-03-10 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-13 |
| 2017-12-31 | $0.00 10-K · filed 2018-03-08 |
| 2016-12-31 | $0.00 10-KT · filed 2017-03-13 |
| 2016-03-31 | $8.60K 10-K · filed 2016-06-28 |
| 2015-03-31 | $49.80K 10-K · filed 2015-05-19 |
| 2014-03-31 | $62.88K 10-K · filed 2014-06-25 |
| 2013-03-31 | $111.79K 10-K · filed 2013-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |